Webinar: Overlap Between NAFLD and ALD: Clinical Challenges and Future Directions

Date: Tuesday, August 16, 1:00 pm - 2:00 pm (EDT)
Presenters: Marco Arrese, MD, FAASLD | Winston Dunn, MD
Moderators: Ashwani K. Singal, MD, MS, FACG, FAASLD | Juan Pablo Arab, MD

Patients with overlapping nonalcoholic fatty liver disease (NAFLD) and alcohol-related liver disease (ALD) are commonly excluded from clinical studies. This webinar will review the overlapping pathophysiology, shared genetic-epigenetic factors and the reciprocal interaction of these factors to determine liver disease prognosis. In particular, we will discuss the data regarding alcohol consumption in NAFLD and obesity/metabolic syndrome in ALD.

About the Presenters

Marco Arrese, MD, FAASLD

Marco Arrese, MD, FAASLD is Professor of Medicine and Head of the Department of Gastroenterology at Pontificia Universidad Catolica de Chile School of Medicine in Santiago. Trained in Chile and the United States (Yale University), he is an expert in liver diseases and has focused his research activities in both cholestatic and fatty liver diseases. He has published more than 200 peer-reviewed papers on gastrointestinal and liver diseases in biomedical journals and delivered more than 100 lectures in national and international meetings. He has been president of the Chilean Society of Gastroenterology and has been elected fellow of the American college of physicians (FACP) and the American Association of the study of the liver (FAASLD). He is also a member of the European Association for the study of the liver (EASL) and the Latin-American association of the study of the liver (ALEH) where he coordinates the special interest group of NAFLD. He has served as a member of the editorial board of Journal of Hepatology, HEPATOLOGY and Annals of Hepatology as well as has acted as reviewer of multiple liver journals.

presenter

Winston Dunn, MD

Winston Dunn, MD is an associate professor for the University of Kansas Medical Center. His expertise includes alcohol-associated liver disease, NASH clinical trials and cirrhosis regression after HCV treatment.

Dr. Dunn has served as editorial board member for Journal of Clinical and Translational Hepatology. He is currently the Education Chair of the Alcohol-associated Liver Disease (ALD) Special Interest Group Education Sub-Committee for the American Association for the Study of Liver Diseases (AASLD). He is the site Principal Investigator for several multinational studies involving NASH treatment. Currently, his research is funded by K23 Mentored Patient-Oriented Research Career Development Award, Lied Pre-Clinical and Clinical Research Pilot Grant Program, and Gilead NASH Models of Care ISR Program.

About the Moderators

Ashwani K. Singal, MD, MS, FACG, FAASLD

Dr. Singal is a professor of medicine at the University of South Dakota, Sanford School of Medicine; transplant hepatologist at the Avera transplant institute; and health research scientist at the VA Sioux Falls. He also directs the hepatology elective course for the senior medical students at the Sanford SOM and is Chief of clinical research at the Avera transplant institute.

With clinical and translational research interests in alcoholic and non-alcoholic fatty liver diseases, renal injury in cirrhosis, and porphyria, Dr. Singal’s research has been funded by the American College of Gastroenterology, National Institute of Health, and pharmaceutical industry. He has over 240 original peer reviewed articles in national / international journals and book chapters. His editorial activities include 

- Editorial board: Hepatology, Liver Transplantation, Seminars Liver Disease

- Guest Editor: Clinical liver disease, Frontiers in Gastroenterology, Translational Gastroenterology Hepatology, Current Hepatology Reports, and Metabolism and Organ Damage 

- Editor in Chief: Translational Gastroenterology Hepatology 

- Associate Editor: Digestive Liver Disease, PLoS One, Journal of Clinical Translational Hepatology, and Journal of Clinical and Experimental Hepatology.

Apart from reviewing research grants and scientific research abstracts for the AGA and AASLD, Dr. Singal is on the study section for the NIH. He is a lead author on ACG guidelines for alcoholic liver disease, co-authored guidelines on vascular disorders of the liver, and is currently co-authoring guidelines on nutritional management of patients with cirrhosis and revised guidelines on alcohol-associated liver disease. Dr. Singal has been awarded the prestigious Edgar Achkar Visiting Professorship by the ACG. He is regularly serving various committees of the AASLD since 2010 and chaired the special interest group on alcohol-related liver disease (2020-2021) of the AASLD.

Juan Pablo Arab, MD

Juan Pablo Arab, MD is an Associate Professor of Medicine at the Pontificia Universidad Catolica de Chile School of Medicine. Trained at the Pontificia Universidad Catolica, Chile and Mayo Clinic, Rochester, MN, USA. Dr. Arab is a Gastroenterology and Hepatology specialist, Transplant Hepatologist, and Clinical Researcher with an interest in clinical/translational research and epidemiology in alcohol-related liver disease and non-alcoholic fatty liver disease. He is the Director for Living Donor Liver Transplantation at his institution. He has published more than 130 peer-reviewed papers, co-authored several book chapters, and delivered lectures on liver-related topics at national and international meetings. He is an Associate Editor for Hepatology (flagship AASLD journal). Additionally, he is spearheading international collaboration groups aiming to study alcohol-associated liver disease and non-alcoholic fatty liver disease (AH-LATIN and Global AlcHep BigData Network). Dr. Arab is a member of the AASLD Global Outreach and Engagement Committee. He is currently the Secretary and elected Vice-Chair of the Special Interest Group on alcohol-associated liver disease of the AASLD. Additionally, he is the elected President of the Chilean Hepatology Association and a member of the Education & Scholarship Committee of the International Liver Transplantation Society (ILTS).

Content Contributor

Nonalcoholic Fatty Liver Disease SIG